Haloperidol, Promethazine (Phenergan), and Lorazepam in the Same Syringe
Haloperidol and lorazepam can be safely mixed and administered in the same syringe, but promethazine should NOT be added to this combination—it must be given as a separate injection. 1
Physical Compatibility Evidence
- The American Academy of Pediatrics explicitly states that combinations of a butyrophenone (haloperidol) and a benzodiazepine (lorazepam) may be administered in the same syringe 1
- There is no published evidence supporting the physical or chemical compatibility of all three medications (haloperidol, promethazine, and lorazepam) in a single syringe 1
Recommended Two-Injection Approach
Option 1: Haloperidol + Lorazepam (One Syringe) + Promethazine (Separate)
- First injection: Haloperidol 5 mg + lorazepam 2 mg mixed in the same syringe 1, 2, 3
- Second injection: Promethazine 25-50 mg given separately 1, 4
- This approach provides the additive calming effects of haloperidol-lorazepam while adding promethazine's antihistamine properties to reduce extrapyramidal symptoms 1, 3
Option 2: Haloperidol + Promethazine (Separate Syringes) Without Lorazepam
- Haloperidol 5-10 mg + promethazine 25-50 mg given as separate injections 1, 4
- This combination is highly effective, with more patients tranquil or asleep by 20 minutes compared to haloperidol alone (NNT 7) 4, 5
- Promethazine significantly reduces the risk of acute dystonia that occurs with haloperidol monotherapy (19.48 times higher risk with haloperidol alone) 5
Clinical Efficacy Comparison
- Haloperidol + lorazepam combination produces the most rapid tranquilization, with significant superiority at hour 1 on agitation scales compared to either drug alone 3
- Haloperidol + promethazine is more effective than haloperidol alone by 20 minutes (RR 0.65) and prevents the unacceptably high dystonia rates seen with haloperidol monotherapy 5
- Adding lorazepam to haloperidol does NOT reduce extrapyramidal symptoms—only promethazine provides this protection 5
Critical Safety Warnings
Respiratory Depression Risk
- The FDA black box warning states that combining lorazepam with haloperidol has resulted in apnea, coma, bradycardia, arrhythmia, cardiac arrest, and death 6
- When benzodiazepines and antipsychotics are combined, close cardiorespiratory monitoring with pulse oximetry is mandatory 1, 6
- Patients must be observed for at least 8 hours and should not ambulate unassisted during this period 6
QTc Prolongation
- All three medications can prolong the QTc interval, with additive effects when combined 1
- Baseline ECG should be obtained if feasible, and continuous cardiac monitoring is recommended 1, 2
- Haloperidol causes 7 ms mean QTc prolongation, and risk increases with combination therapy 7
Drug Interaction Concerns
- The FDA specifically warns about marked sedation and rare deaths reported with haloperidol-lorazepam combinations 6
- Lorazepam's CNS depressant effects are significantly enhanced by phenothiazines (promethazine) and antipsychotics (haloperidol) 6
Practical Administration Algorithm
- Assess cardiac risk factors and obtain ECG if time permits 1, 7
- Choose your combination based on clinical scenario:
- Reduce doses by 50% in elderly patients (haloperidol 0.25-0.5 mg, lorazepam 1 mg) 2
- Monitor continuously for respiratory depression, excessive sedation, and cardiac arrhythmias for minimum 8 hours 1, 6
- Have reversal agents available: Flumazenil for lorazepam, diphenhydramine for dystonia 1
Common Pitfalls to Avoid
- Never assume all three drugs are compatible in one syringe—there is no evidence supporting this, and pharmaceutical incompatibility could result in precipitation or inactivation 1
- Do not use haloperidol alone without either promethazine or having diphenhydramine immediately available—dystonia rates are unacceptably high (NNH 15) 5
- Avoid this combination in patients with Parkinson's disease or Lewy body dementia—haloperidol will cause severe extrapyramidal symptoms regardless of promethazine 7, 2
- Do not give lorazepam-haloperidol combinations without continuous monitoring capabilities—the FDA reports deaths from this combination 6